Skip to content
Screener

Generate Biomedicines, Inc. GENB EPS (Diluted)

EPS (Diluted) at other companies

Veradermics logo
VeradermicsMANE
-$1.32+93.3%
BK
BKBK
$2.24+41.8%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
-$0.05+54.5%
Schering-Plough logo
Schering-PloughSGP
-$0.69+82.6%
Dycom Industries logo
Dycom IndustriesDY
$3.00+43.5%
Target logo
TargetTGT
$1.71-24.7%

Other financials

Income statement

See full
Revenue$6.3M-37.7%
Operating income-$71.6M-19.1%
Net income-$67.3M-28.3%

Balance sheet

See full
Cash & equivalents$135.4M-12.3%
Total debt$62.6M—
Total equity$456.0M+188%
Total assets$561.7M—

Cash flow

See full
Operating cash flow-$57.9M-18.9%
CapEx$933.0K+506%
Free cash flow-$58.9M-20.4%

Valuation

See full
Market cap$1.86B+19.8%
Enterprise value$1.78B—
P/S57.2×—

Profitability

See full
Operating margin-751.2%—
Net margin-685.9%—
FCF margin-756.9%—

Returns & leverage

See full
Return on equity2,979.4%—
Debt / equity0.1×—
Current ratio8.3×—

Where this comes from

Reported directly by Generate Biomedicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Generate Biomedicines, Inc.’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 6:01 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336437

FAQ

What is Generate Biomedicines, Inc.'s EPS (diluted)?
Generate Biomedicines, Inc. (GENB) reported EPS (diluted) of -$0.52 in Q2 2026.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Generate Biomedicines, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude